Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 143 participants.

Also called NCT02178098

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 143 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02178098
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02178098. Randomized; quadruple masking; primary purpose treatment. Start 2014-06-16 (actual); primary completion 2015-05-22 (actual). Results posted on 2023-04-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
Condition
Hypercholesterolemia
Condition
Hypertension
Intervention (Drug)
ETC-1002
Intervention (Drug)
Placebo
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02178098
Content hash
dda0fd7cf1a77b00048e25d56d06ab4a3738fb55ed4a7dc13f8922f926867ce2